CENTERVILLE, MA � January 20, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce one of UV Flu's distributors, INE Global, has placed an order with The Rogerson House, one of Boston's pre-eminent Assisted Living Facilities. As one of 26 facilities serving almost 1500 Boston-area families, the facility caters to people with memory loss, and is one of the few organizations that actually encourage their residents to own pets. The units are going to be used in the dining and common areas of the facility, where odor control alongside the UV-400s' bacteria killing capabilities will offer a significant decrease in compromised air quality and prevalence of odors.
"We are finding that our products' ability to reduce odors, including from pets and cigarettes has become almost as big of a selling point as the UV-400's ability to kill bacteria and other organic contaminants," said John Lennon, President of UV Flu. "We believe strongly that keeping staff, patients, and visitors safe from the spread of airborne bacteria and viruses should be a national concern. Even though we are still at an early stage with respect to increasing awareness of the dangers of poor indoor air quality, we aim to demonstrate the value of our products by getting them into action, especially in particularly illness-prone environments."
In related news, the Company announced a shipment to Boston's Liberty Hotel, one of the city's foremost 5 Star Hotels, featuring 298 guest rooms and suites.
"The Liberty Hotel is a cutting edge, pet friendly property, with a variety of celebrities counted among their frequent guests," said John Lennon, President of UV Flu. "As such, odor control, particularly from pet odors, or cigarette smoke in non-smoking rooms, has become an increasingly critical element in delivering customer satisfaction. The UV-400 breaks down cigarette smoke and other odors, while killing airborne contaminants, making it a must for most hotel properties."
The Company invites all Hospitality Sector Managers, Operations Leaders and Purchasing Agents to contact UV Flu Technologies to discuss the solutions now offered in a growing number of premier properties and to find out how the UV-400 can offer immediate relief from airborne odors and bacteria in chronic problem spaces within almost any commercial property or public facility.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
No comments:
Post a Comment